DOI: 10.1055/s-00000133

Gastroenterologie up2date


Debiec-Rychter M, Sciot R, Verweij J, Casali P, LeCesne A, Zalcberg J, Hohenberger P, Blay JY, Schlemmer M, VanGlabbeke M. et al.
KIT mutations should guide dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Results of mutation analysis in 377 patients entered into a randomized study. 
Nature Med ; : (submitted)-  

Download Bibliographical Data

Search in: